SS&C Intralinks and Capital for Cures host an evening in London on 10 June 2026 focused on royalty financing. Globally a $20B+ annual market, royalty financing allows biotech and pharma companies to raise capital by selling a share of future product revenues, without diluting shareholders or taking on traditional debt. The mechanism has become a core part of the US life sciences funding stack, while European biotechs remain underserved and most deal flow continues to concentrate in North America. The evening brings together biotech executives, pharma BD teams, family offices, and specialist investors actively deploying into European royalty deals, featuring a moderated panel followed by extended networking.
Panel: Royalty Financing, Aligning Capital and Science
Moderator: Sebastian Gensior, Founder, Capital for Cures
Speakers:
Adina Krausz (CEO, InnoSource Ventures; Board Member, Toledo Capital AG)
David Bryant (Non-Executive Advisor EU & UK, HealthCare Royalty / HCRx)
Roland Petrenkó (Head of Pharma & Healthcare EMEA, SS&C Intralinks)
Format: 17:00 welcome drinks · 17:45 panel · 18:25 networking reception
Audience: Series A/B biotechs, pharma BD/M&A teams, royalty and credit funds writing €10m+ tickets, family offices
